Auris Medical is developing novel therapeutics for local treatment of inner ear disorders.
We have currently two late-stage development programs: Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Keyzilen®'s therapeutic time window beyond the acute stage is currently being evaluated as part of the TACTT3 clinical trial in Europe.
Early-stage development programs focus on vestibular disorders (AM-125), a second generation tinnitus treatment (AM-102) and a treatment for a major rhinology indication (AM-123).
1) Dates of key milestones are indicative and subject to change.
ASNHL: Acute Sensorineural Hearing Loss; FPI: First Patient In.